Cell-Penetrating Peptide PepFect14 Successfully Delivers Gene Therapy to the Nucleus of Myotonic Dystrophy Cells | Research

The takeaway

Only the cell-penetrating peptide PepFect14 — not nona-arginine — could deliver antisense oligonucleotides to the nucleus of myotonic dystrophy muscle cells, where upper nanomolar concentrations were needed to correct disease-related RNA defects.

Nuclear delivery = therapeutic effect
Only PF14 achieved nuclear delivery; nona-arginine got ASOs into cells but not nuclei — and only nuclear delivery corrected the disease phenotype

What the researchers found

Of two cell-penetrating peptides tested for delivering antisense oligonucleotides (ASOs) to myotonic dystrophy muscle cells, only PepFect14 (PF14) successfully delivered ASOs to the nucleus and corrected disease-typical abnormal splicing in a dose-dependent manner. Nona-arginine facilitated cellular uptake but failed to deliver ASOs to the nucleus. PF14 also protected ASOs from degradation. Nuclear ASO concentrations in the upper nanomolar range were required to dissolve MBNL1 protein foci — a hallmark of myotonic dystrophy type 1 (DM1).

Why it matters

Myotonic dystrophy type 1 is the most common adult muscular dystrophy, and ASOs targeting the disease-causing RNA expansion are a leading therapeutic approach. But getting ASOs into the nucleus where they need to work is a major delivery challenge. This study shows that the right cell-penetrating peptide (PF14) can solve this problem — not just getting cargo into cells, but specifically into the nucleus. It also establishes the critical concentration threshold needed for therapeutic effect.

The numbers in context

Upper nanomolar nuclear concentration required · PF14 = successful nuclear delivery · Nona-arginine = failed nuclear delivery · Dose-dependent splicing correction · MBNL1 foci dissolution confirmed

How the study worked

DM1 muscle cell model treated with ASOs complexed with either nona-arginine or PepFect14 cell-penetrating peptides. Therapeutic effect measured by correction of abnormal RNA splicing. Nuclear delivery confirmed by time-lapse confocal microscopy. ASO integrity assessed by fluorescence lifetime imaging (distinguishing intact ASO from degraded fluorophore). Nuclear concentration quantified by fluorescence correlation spectroscopy combined with immunofluorescence for MBNL1 foci.

What this study cannot tell us

This is an in vitro cell culture study — the DM1 muscle cell model doesn't replicate the full complexity of muscle tissue in vivo. The nuclear concentration threshold (upper nanomolar) is measured in culture and may differ in living tissue where delivery barriers are more complex. PF14's performance in cell culture may not translate to systemic delivery in animals or humans.

How to read the evidence

This is a rigorous in vitro mechanistic study using advanced quantitative imaging techniques (FLIM, FCS, confocal time-lapse). The technical quality is high, but all work is in cultured cells — in vivo delivery and efficacy remain undemonstrated.

When this study was published

Published in 2019, this study provides foundational data for CPP-mediated ASO delivery in DM1. The DM1 ASO field has continued to advance, with clinical trials testing various delivery approaches.

The bigger picture

This study highlights a critical distinction in cell-penetrating peptide research: getting cargo into a cell is not the same as getting it to the right place within the cell. For nuclear-acting drugs like ASOs, endosomal escape and nuclear translocation are separate hurdles. PF14's success where nona-arginine failed provides concrete data for designing better CPP delivery systems. As ASO therapies expand (nusinersen for SMA, eteplirsen for DMD), understanding delivery thresholds becomes essential for dosing and efficacy optimization.

Questions still open

Can PF14-mediated ASO delivery achieve therapeutic nuclear concentrations in living muscle tissue, not just cell culture?
What is PF14's mechanism for nuclear translocation that nona-arginine lacks?
Could this delivery approach be combined with existing DM1 ASO candidates in clinical development?

Common questions

What is myotonic dystrophy and why do ASOs need to reach the nucleus?

Myotonic dystrophy type 1 (DM1) is caused by an expanded DNA repeat that produces toxic RNA molecules. These RNA molecules get stuck in the cell nucleus and form clumps with MBNL1 protein, disrupting normal RNA processing. ASOs designed to block these toxic RNA molecules need to reach the nucleus where the problem occurs — getting into the cell cytoplasm alone isn't enough.

Why did PepFect14 work but nona-arginine didn't?

Both peptides got ASOs into cells, but through different pathways. Nona-arginine apparently delivered ASOs into endosomes (cellular compartments) that never released their cargo to the nucleus. PF14 not only facilitated cellular uptake but also mediated nuclear translocation — getting ASOs through the nuclear envelope to where they're needed. PF14 also protected ASOs from degradation, ensuring they arrived intact.

Read the original research

The nuclear concentration required for antisense oligonucleotide activity in myotonic dystrophy cells.

FASEB journal : official publication of the Federation of American Societies for Experimental Biology, 33(10), 11314-11325

View on PubMed ↗Publisher’s paper ↗

Citation

van der Bent, M Leontien; Paulino da Silva Filho, Omar; Willemse, Marieke; Hällbrink, Mattias; Wansink, Derick G; Brock, Roland. (2019). The nuclear concentration required for antisense oligonucleotide activity in myotonic dystrophy cells.. FASEB journal : official publication of the Federation of American Societies for Experimental Biology, 33(10), 11314-11325. https://doi.org/10.1096/fj.201900263R